Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC

1 de julio de 2026 actualizado por: Hansoh BioMedical R&D Company

A PHASE Ib STUDY OF THE SAFETY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY OF HS-20122 COMBINED THERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS

This is a multi-center, open-label, phase I study to evaluate the safety, efficacy, pharmacokinetics (PK), and immunogenicity of HS-20122 combined therapy in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).

Descripción general del estudio

Descripción detallada

This is a multi-center, open-label, phase I study to evaluate the safety, efficacy, pharmacokinetics (PK), and immunogenicity of HS-20122 combination therapy in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC). A dose exploration stage of each combination therapy will be conducted in subjects with advanced or metastatic NSCLC patients who experienced disease progression (PD) on or after prior treatments, to explore appropriate doses. In addition, an dose-expansion stage will be conducted in appropriate target populations based on the data obtained in the dose exploration stage to further explore the safe and efficacy.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

396

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Guangdong
      • Guangzhou, Guangdong, Porcelana
        • Reclutamiento
        • Ethics Committee of Sun Yat-sen University Cancer Center
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  1. Locally advanced or metastastic NSCLC;
  2. Received at least 1 line SoC,or treatment naïve;
  3. With at least 1 target lesion according to RECIST 1.1.
  4. Appropriate organ function
  5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-1 and no deterioration within 2 weeks prior to the first dose.
  6. Minimum expected survival longer than 12 weeks
  7. Female subjects of childbearing potential are willing to take appropriate contraceptive measures and should not breastfeed from signing the informed consent form (ICF) through 6 months after the last dose; male subjects are willing to use barrier contraception (i.e., condom) from signing the ICF through 6 months after the last dose.
  8. Voluntarily participate in this clinical trial, understand the study procedures, and be able to sign written informed consent form.

Exclusion Criteria:

  1. Insufficient wash out duration of prior systemic anticancer therapy
  2. Local radiotherapy within 2 weeks prior to first dose of investigational drug
  3. Pleural/abdominal effusion requires clinical intervention
  4. Major surgery within 4 weeks prior to first dose of investigational drug
  5. History of drugs may prolong QT interval
  6. Have any grade ≥ 2 residual toxicity according to Common Terminology Criteria for Adverse Events (CTCAE, version 5.0) from prior anti-tumor therapy (except alopecia and residual neurotoxicity).
  7. Presence of brain metastasis or carcinomatous meningtitis
  8. History of other primary malignancies
  9. Significant, uncontrolled, or active cardiovascular diseases
  10. Severe or poorly controlled diabetes
  11. Extremely obesity or emaciation
  12. Clinically significant bleeding symptoms or obvious bleeding tendency within 1 month prior to the first dose
  13. Severe arteriovenous thrombotic events (e.g., deep venous thrombosis, pulmonary embolism) within 3 months prior to the first dose
  14. Severe infection within 4 weeks
  15. History of systemic glucocorticoids over 28 days prior to first dose of investigational drug
  16. Presence of known active infectious diseases,
  17. Prensence of ophthalmological abnormalities.

17.Presence of hepatic encephalopathy, Hepato-renal Syndrome 18.Presence or history of confirmed or suspected ILD; 19.Prior history of significant neurological or mental disorders, including conditions that interfere with assessment, such as epilepsy, dementia, or major depressive disorder.

20.History of severe allergy, or history of hypersensitivity to any active or inactive ingredient of investigational drugs.

21.Presence of any conditions that jeopardize subject safety or interfere with study assessments as judged by the investigator.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: HS-20122+Aumolertinib
EGFR mut NSCLC, receive HS-20122+Aumolertinib
Experimental: HS-20122+Adbrelimab
EGFRwt NSCLC,receive HS-20122+Adbrelimab
Experimental: HS-20122+Adbrelimab+Platinum-based Chemo
EGFR wt NSCLC,receive HS-20122+Adbrelimab+ Platinum-based Chemo

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
EAE
Periodo de tiempo: Durante la duración completa de este ensayo, aproximadamente 2 años
incidencia de Eventos Adversos Graves evaluados por el Investigador, clasificados según CTCAE V5.0
Durante la duración completa de este ensayo, aproximadamente 2 años
RP2D for Combination
Periodo de tiempo: Through the full duration of this trial, approximately 2 years
To evaluate the potent and tolerated of combination(s) and dosage(s) of HS-20122 based therapy in subjects with locally advanced or metastatic NSCLC who have experienced disease progression on or after prior treatment, which suitable for a Phase II trial
Through the full duration of this trial, approximately 2 years
ORR
Periodo de tiempo: Through the full duration of this trial, approximately 2 years;
Investigator evaluated overall response rate, to evaluate the efficacy of each combination;
Through the full duration of this trial, approximately 2 years;
TEAE
Periodo de tiempo: Through the full duration of this trial, approximately 2 years;
incidence of Investigator evaluated Treatment Emerged Adverse Events, graded per CTCAE V5.0
Through the full duration of this trial, approximately 2 years;
TRAE
Periodo de tiempo: Through the full duration of this trial, approximately 2 years;
incidence of Investigator evaluated Treatment Related Adverse Events, graded per CTCAE V5.0
Through the full duration of this trial, approximately 2 years;

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Duration of Response
Periodo de tiempo: Through the full duration of this trial ,approximately 2 years
Investigator evaluated Duration of Response
Through the full duration of this trial ,approximately 2 years
Disease Control Rate
Periodo de tiempo: Through the full duration of this trial ,approximately 2 years;
Investigator evaluated Disease Control Rate
Through the full duration of this trial ,approximately 2 years;
Progression Free Survival
Periodo de tiempo: Through the full duration of this trial, approximately 2 years;
Investigator evaluated duration of Progression Free Survival
Through the full duration of this trial, approximately 2 years;
Overall Survival
Periodo de tiempo: Through the full duration of this trial ,approximately 2 years;
Investigator evaluated duration of Overall Survival
Through the full duration of this trial ,approximately 2 years;
PK parameter
Periodo de tiempo: Through the full duration of this trial, approximately 2 years;
blood concentration of combo agents
Through the full duration of this trial, approximately 2 years;
Immuogencity
Periodo de tiempo: Through the full duration of this trial ,approximately 2 years;
positive rate of drug specific antibody
Through the full duration of this trial ,approximately 2 years;

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

15 de junio de 2026

Finalización primaria (Estimado)

31 de octubre de 2028

Finalización del estudio (Estimado)

30 de abril de 2029

Fechas de registro del estudio

Enviado por primera vez

8 de junio de 2026

Primero enviado que cumplió con los criterios de control de calidad

8 de junio de 2026

Publicado por primera vez (Actual)

12 de junio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

6 de julio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

1 de julio de 2026

Última verificación

1 de julio de 2026

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir